Clinical Trial Update: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of PIPE-307 in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• PIPE-307

Snippet

Sponsor: Contineum Therapeutics | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED